Abacavir sulfate - Generic Drug Details

➤ Subscribe for complete access

« Back to Dashboard

What are the generic drug sources for abacavir sulfate and what is the scope of freedom to operate?

Abacavir sulfate is the generic ingredient in seven branded drugs marketed by Aurobindo Pharma Ltd, Hetero Labs Ltd Iii, Viiv Hlthcare, Apotex Inc, Cipla, Mylan Pharms Inc, Strides Pharma, Lupin Ltd, Teva Pharms Usa, and Zydus Pharms, and is included in twenty NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

There are twelve drug master file entries for abacavir sulfate. Thirteen suppliers are listed for this compound. There are eleven tentative approvals for this compound.

Summary for abacavir sulfate

US Patents:	2
Tradenames:	7
Applicants:	10
NDAs:	20
Drug Master File Entries:	12
Finished Product Suppliers / Packagers:	13
Raw Ingredient (Bulk) Api Vendors:	132
Clinical Trials:	65
Patent Applications:	6,453
Formulation / Manufacturing:	see details
What excipients (inactive ingredients) are in abacavir sulfate?	abacavir sulfate excipients list
DailyMed Link:	abacavir sulfate at DailyMed

Recent Clinical Trials for abacavir sulfate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cynthia L Gay, MD	N/A
ViiV Healthcare	N/A
University of North Carolina, Chapel Hill	N/A

See all abacavir sulfate clinical trials

Generic filers with tentative approvals for ABACAVIR SULFATE

Applicant	Application No.	Strength	Dosage Form
⤷ Try it Free	⤷ Try it Free	60MG	TABLET; ORAL
⤷ Try it Free	⤷ Try it Free	60MG; 30MG	TABLET; ORAL
⤷ Try it Free	⤷ Try it Free	60MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for abacavir sulfate

Drug Class	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Nucleoside Reverse Transcriptase Inhibitors Cytochrome P450 1A1 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for abacavir sulfate

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for ABACAVIR SULFATE

Tradename	Dosage	Ingredient	NDA	Submissiondate
ZIAGEN	SOLUTION;ORAL	abacavir sulfate	020978	2012-12-27
ZIAGEN	TABLET;ORAL	abacavir sulfate	020977	2009-01-28

US Patents and Regulatory Information for abacavir sulfate

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma Ltd	ABACAVIR SULFATE AND LAMIVUDINE	abacavir sulfate; lamivudine	TABLET;ORAL	090159-001	Nov 15, 2018	AB	RX	No	No	⤷ Try it Free	⤷ Try it Free				⤷ Try it Free
Apotex Inc	ABACAVIR SULFATE	abacavir sulfate	TABLET;ORAL	201570-001	Dec 17, 2012		DISCN	No	No	⤷ Try it Free	⤷ Try it Free				⤷ Try it Free
Hetero Labs Ltd Iii	ABACAVIR SULFATE	abacavir sulfate	SOLUTION;ORAL	201107-001	Sep 26, 2016	AA	RX	No	No	⤷ Try it Free	⤷ Try it Free				⤷ Try it Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for abacavir sulfate

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	ZIAGEN	abacavir sulfate	SOLUTION;ORAL	020978-001	Dec 17, 1998	⤷ Try it Free	⤷ Try it Free
Viiv Hlthcare	ZIAGEN	abacavir sulfate	SOLUTION;ORAL	020978-001	Dec 17, 1998	⤷ Try it Free	⤷ Try it Free
Viiv Hlthcare	ZIAGEN	abacavir sulfate	TABLET;ORAL	020977-001	Dec 17, 1998	⤷ Try it Free	⤷ Try it Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.